Nippon Shinyaku Co., Ltd. 4516

NS Pharma, Inc. (Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Toru Nakai), has exercised its option rights under the option agreement entered into with AB2 BIO Ltd. (Headquarters: Lausanne, Switzerland, CEO: Djordje Filipovic) in January 2025 regarding Tadekinig alfa. Through the exercise of the option rights, Nippon Shinyaku has obtained exclusive commercialization righ

AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku exercises its exclusive U.S. commercialization option for Tadekinig alfa after AB2 Bio’s positive interactions with U.S. FDALicense covers lead indication in the U.S., Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome in patients with NLRC4 and XIAP mutationsAB2 Bio retains world-wide rights to Tadekinig alfa for all other indications and all ex-U.S. rights for

NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto, Japan; President, Toru Nakai) has entered into an option agreement with Elixirgen Therapeutics, Inc. (Elixirgen; Headquarters, Baltimore, MD; CEO, Aki Ko) under which Nippon Shinyaku may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the treatment of Duchenne muscular dystrop

BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases, today announced that it has entered into an option agreement with Nippon Shinyaku Co., Ltd. (Headquarters, Kyoto, Japan; President, Toru Nakai). Under the terms of the agreement, Elixirgen will be responsible for the development of EXG-7001 for the treatment of Duchenne Muscular Dystrophy (DMD) and Nippon Shinyaku

NS Pharma, Inc. (NS Pharma; Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto, Japan; President: Toru Nakai), has entered into a Sponsored Research Agreement (SRA) with Boston Children's Hospital (Headquarters: Boston, Massachusetts; Chief Executive Officer: Kevin B. Churchwell) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement

An oral argument on a dispute between Nippon Shinyaku, its U.S. subsidiary, NS Pharma, and Capricor is scheduled for Wednesday.

Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenne muscular dystrophy therapy, despite weaker-than-expected quarterly financial results. Earnings and Revenue Miss ExpectationsRegenxbio reported a first-quarter loss of $1.

Capricor Therapeutics (NasdaqGS:CAPR) has filed a lawsuit to rescind its U.S. distribution agreement for deramiocel, its Duchenne muscular dystrophy therapy, with NS Pharma and Nippon Shinyaku. The company argues that flaws in the pricing terms could restrict patient access to deramiocel in the U.S. market. In parallel, Capricor is preparing for potential direct commercialization, including plans to expand manufacturing capacity and strengthen its leadership team. Deramiocel has completed a...

Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku. On t

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpointsGMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd.

Regenxbio Inc (RGNX) reports increased revenue and cash reserves, while advancing key programs and navigating regulatory challenges.